Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 40,900 shares of the company’s stock, valued at approximately $995,000.
Other hedge funds have also modified their holdings of the company. Benjamin F. Edwards & Company Inc. raised its stake in shares of Teva Pharmaceutical Industries by 553.3% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 22,361 shares of the company’s stock valued at $544,000 after purchasing an additional 18,938 shares in the last quarter. IFM Investors Pty Ltd raised its stake in shares of Teva Pharmaceutical Industries by 52.8% in the second quarter. IFM Investors Pty Ltd now owns 43,300 shares of the company’s stock valued at $1,053,000 after purchasing an additional 14,960 shares in the last quarter. Manning & Napier Group LLC acquired a new position in shares of Teva Pharmaceutical Industries in the second quarter valued at $247,000. OppenheimerFunds Inc. raised its stake in shares of Teva Pharmaceutical Industries by 15.5% in the first quarter. OppenheimerFunds Inc. now owns 4,229,508 shares of the company’s stock valued at $72,282,000 after purchasing an additional 566,300 shares in the last quarter. Finally, Private Advisor Group LLC acquired a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at $368,000. Institutional investors own 64.95% of the company’s stock.
Shares of NYSE:TEVA opened at $24.22 on Friday. The company has a current ratio of 1.03, a quick ratio of 0.69 and a debt-to-equity ratio of 1.86. The firm has a market capitalization of $22.86 billion, a price-to-earnings ratio of 6.16, a P/E/G ratio of 2.80 and a beta of 0.72. Teva Pharmaceutical Industries Ltd has a fifty-two week low of $10.85 and a fifty-two week high of $25.14.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, August 2nd. The company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.64 by $0.14. The company had revenue of $4.70 billion for the quarter, compared to analysts’ expectations of $4.75 billion. Teva Pharmaceutical Industries had a positive return on equity of 19.92% and a negative net margin of 47.98%. The business’s revenue for the quarter was down 17.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.02 earnings per share. research analysts predict that Teva Pharmaceutical Industries Ltd will post 2.67 EPS for the current fiscal year.
A number of research analysts recently commented on the company. Mizuho restated a “buy” rating and issued a $28.00 target price on shares of Teva Pharmaceutical Industries in a research note on Thursday. Cantor Fitzgerald restated a “hold” rating and issued a $25.00 target price on shares of Teva Pharmaceutical Industries in a research note on Thursday. ValuEngine upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Tuesday, August 7th. Barclays set a $23.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Thursday, August 2nd. Finally, Morgan Stanley upped their price target on Teva Pharmaceutical Industries from $19.00 to $20.00 and gave the company an “equal weight” rating in a research report on Friday, August 3rd. Nine equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eight have given a buy rating to the company. Teva Pharmaceutical Industries has a consensus rating of “Hold” and an average price target of $20.45.
In other news, EVP Iris Beck Codner sold 4,165 shares of the stock in a transaction on Thursday, August 9th. The stock was sold at an average price of $22.70, for a total transaction of $94,545.50. Following the sale, the executive vice president now owns 8,290 shares in the company, valued at $188,183. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sven Dethlefs bought 2,000 shares of the firm’s stock in a transaction dated Friday, August 3rd. The shares were acquired at an average price of $21.92 per share, for a total transaction of $43,840.00. Following the acquisition, the executive vice president now directly owns 6,445 shares of the company’s stock, valued at approximately $141,274.40. The disclosure for this purchase can be found here. 0.43% of the stock is currently owned by corporate insiders.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Article: Asset Allocation, Balancing Your Investments
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.